vs
奥飞娱乐（MAX）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
奥飞娱乐的季度营收约是Orthofix Medical Inc.的1.4倍（$310.0M vs $219.9M），奥飞娱乐净利率更高（4.5% vs -1.0%，领先5.5%），奥飞娱乐同比增速更快（17.3% vs 2.0%），过去两年奥飞娱乐的营收复合增速更高（31.9% vs 8.0%）
奥飞娱乐股份有限公司由蔡东青于1993年创立，是一家中国跨国综合企业集团，主营动漫、玩具、传媒资产与娱乐业务，2016年由原奥飞动漫更名而来。集团拥有国漫平台有妖气，还在美国设有影视公司奥飞影业，并宣布将在美国设立动漫业务部门。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
MAX vs OFIX — 直观对比
营收规模更大
MAX
是对方的1.4倍
$219.9M
营收增速更快
MAX
高出15.3%
2.0%
净利率更高
MAX
高出5.5%
-1.0%
两年增速更快
MAX
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $310.0M | $219.9M |
| 净利润 | $14.0M | $-2.2M |
| 毛利率 | 15.1% | 71.1% |
| 营业利润率 | 7.2% | 0.2% |
| 净利率 | 4.5% | -1.0% |
| 营收同比 | 17.3% | 2.0% |
| 净利润同比 | 701.8% | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MAXOFIX
| Q1 26 | $310.0M | — | ||
| Q4 25 | $291.2M | $219.9M | ||
| Q3 25 | $306.5M | $205.6M | ||
| Q2 25 | $251.6M | $203.1M | ||
| Q1 25 | $264.3M | $193.6M | ||
| Q4 24 | $300.6M | $215.7M | ||
| Q3 24 | $259.1M | $196.6M | ||
| Q2 24 | $178.3M | $198.6M |
净利润MAXOFIX
| Q1 26 | $14.0M | — | ||
| Q4 25 | $31.4M | $-2.2M | ||
| Q3 25 | $14.9M | $-22.8M | ||
| Q2 25 | $-18.7M | $-14.1M | ||
| Q1 25 | $-1.9M | $-53.1M | ||
| Q4 24 | $4.6M | $-29.1M | ||
| Q3 24 | $9.5M | $-27.4M | ||
| Q2 24 | $3.6M | $-33.4M |
毛利率MAXOFIX
| Q1 26 | 15.1% | — | ||
| Q4 25 | 15.4% | 71.1% | ||
| Q3 25 | 14.2% | 72.2% | ||
| Q2 25 | 15.0% | 68.7% | ||
| Q1 25 | 15.8% | 62.8% | ||
| Q4 24 | 16.3% | 69.0% | ||
| Q3 24 | 15.1% | 68.7% | ||
| Q2 24 | 17.8% | 67.8% |
营业利润率MAXOFIX
| Q1 26 | 7.2% | — | ||
| Q4 25 | 7.7% | 0.2% | ||
| Q3 25 | 6.4% | -8.3% | ||
| Q2 25 | -8.0% | -7.9% | ||
| Q1 25 | 0.0% | -25.2% | ||
| Q4 24 | 6.1% | -5.3% | ||
| Q3 24 | 6.0% | -9.6% | ||
| Q2 24 | 3.6% | -12.5% |
净利率MAXOFIX
| Q1 26 | 4.5% | — | ||
| Q4 25 | 10.8% | -1.0% | ||
| Q3 25 | 4.9% | -11.1% | ||
| Q2 25 | -7.4% | -6.9% | ||
| Q1 25 | -0.7% | -27.4% | ||
| Q4 24 | 1.5% | -13.5% | ||
| Q3 24 | 3.7% | -13.9% | ||
| Q2 24 | 2.0% | -16.8% |
每股收益（稀释后）MAXOFIX
| Q1 26 | — | — | ||
| Q4 25 | $0.50 | $-0.05 | ||
| Q3 25 | $0.26 | $-0.57 | ||
| Q2 25 | $-0.33 | $-0.36 | ||
| Q1 25 | $-0.04 | $-1.35 | ||
| Q4 24 | $0.09 | $-0.76 | ||
| Q3 24 | $0.17 | $-0.71 | ||
| Q2 24 | $0.07 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.1M | $82.0M |
| 总债务越低越好 | $163.5M | — |
| 股东权益账面价值 | — | $450.0M |
| 总资产 | $367.7M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MAXOFIX
| Q1 26 | $26.1M | — | ||
| Q4 25 | $46.9M | $82.0M | ||
| Q3 25 | $38.8M | $62.9M | ||
| Q2 25 | $85.4M | $65.6M | ||
| Q1 25 | $63.6M | $58.0M | ||
| Q4 24 | $43.3M | $83.2M | ||
| Q3 24 | $32.3M | $30.1M | ||
| Q2 24 | $28.7M | $26.4M |
总债务MAXOFIX
| Q1 26 | $163.5M | — | ||
| Q4 25 | $153.4M | — | ||
| Q3 25 | $155.7M | $157.2M | ||
| Q2 25 | $158.0M | $157.0M | ||
| Q1 25 | $160.2M | $156.9M | ||
| Q4 24 | $162.4M | $157.0M | ||
| Q3 24 | $164.7M | $118.5M | ||
| Q2 24 | $166.9M | $118.0M |
股东权益MAXOFIX
| Q1 26 | — | — | ||
| Q4 25 | $4.2M | $450.0M | ||
| Q3 25 | $-29.8M | $442.5M | ||
| Q2 25 | $-3.8M | $458.3M | ||
| Q1 25 | $7.9M | $458.3M | ||
| Q4 24 | $2.4M | $503.1M | ||
| Q3 24 | $-8.4M | $525.9M | ||
| Q2 24 | $-24.4M | $546.0M |
总资产MAXOFIX
| Q1 26 | $367.7M | — | ||
| Q4 25 | $383.8M | $850.6M | ||
| Q3 25 | $266.2M | $832.6M | ||
| Q2 25 | $249.4M | $837.2M | ||
| Q1 25 | $240.0M | $823.1M | ||
| Q4 24 | $262.4M | $893.3M | ||
| Q3 24 | $236.1M | $867.9M | ||
| Q2 24 | $198.2M | $882.0M |
负债/权益比MAXOFIX
| Q1 26 | — | — | ||
| Q4 25 | 36.88× | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | 20.23× | 0.34× | ||
| Q4 24 | 68.31× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流MAXOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-7.4M | $27.7M | ||
| Q3 25 | $23.6M | $12.4M | ||
| Q2 25 | $25.7M | $11.6M | ||
| Q1 25 | $23.7M | $-18.4M | ||
| Q4 24 | $14.5M | $23.7M | ||
| Q3 24 | $8.1M | $11.7M | ||
| Q2 24 | $21.6M | $9.0M |
自由现金流MAXOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-7.5M | $16.8M | ||
| Q3 25 | $23.6M | $2.5M | ||
| Q2 25 | $25.5M | $4.5M | ||
| Q1 25 | $23.6M | $-25.1M | ||
| Q4 24 | $14.5M | $15.2M | ||
| Q3 24 | $8.0M | $6.3M | ||
| Q2 24 | $21.5M | $-360.0K |
自由现金流率MAXOFIX
| Q1 26 | — | — | ||
| Q4 25 | -2.6% | 7.6% | ||
| Q3 25 | 7.7% | 1.2% | ||
| Q2 25 | 10.2% | 2.2% | ||
| Q1 25 | 8.9% | -13.0% | ||
| Q4 24 | 4.8% | 7.0% | ||
| Q3 24 | 3.1% | 3.2% | ||
| Q2 24 | 12.0% | -0.2% |
资本支出强度MAXOFIX
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 4.9% | ||
| Q3 25 | 0.0% | 4.8% | ||
| Q2 25 | 0.1% | 3.5% | ||
| Q1 25 | 0.0% | 3.5% | ||
| Q4 24 | 0.0% | 4.0% | ||
| Q3 24 | 0.0% | 2.7% | ||
| Q2 24 | 0.1% | 4.7% |
现金转化率MAXOFIX
| Q1 26 | — | — | ||
| Q4 25 | -0.24× | — | ||
| Q3 25 | 1.58× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.13× | — | ||
| Q3 24 | 0.85× | — | ||
| Q2 24 | 5.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAX
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
